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Improving treatment outcome for children with HIV
Over 2 million children are infected with HIV, and around 
700 children die of HIV/AIDS-related causes every 
day. Almost all children with HIV infection have been 
infected through perinatal transmission, and without 
antiretroviral treat  ment over half will die before the age 
of 2 years.
1
Antiretrovirals have had a dramatic eﬀ  ect on the course 
of HIV/AIDS in children. Trials show excellent long-term 
outcomes with protease inhibitors and non-nucleoside 
reverse-transcriptase inhibitors,
2 and current guidelines 
recommend starting antiretroviral therapy in children 
as soon as possible after diagnosis of HIV infection.
3 
Poor availability of eﬃ   cient  antiretroviral  regimens, 
unclear strategies for optimum drug sequencing, and 
maintenance of high adherence from infancy and 
throughout adolescence to adulthood are important 
challenges to long-term treatment success.
4
In  The Lancet, the PLATO II investigators
5 report a 
cohort collaboration in Europe which assessed the 
risk of triple-class virological failure in children. Just 
over 1000 children were followed up for a median 
of 4·2 years. By the end of follow-up, 335 (33%) had 
started a drug from a third class, of whom 105 were on 
a failing regimen. The estimated cumulative proportion 
of children with triple-class virological failure was 12% 
at 5 years; when the analysis was restricted to children 
exposed to boosted protease inhibitors, the cumulative 
proportion was about twice that seen in adults in the 
same cohort collaboration (8·2% vs 4·2%). Older age 
when starting antiretroviral therapy (10–15 years) was 
associated with an increased risk of triple-class virological 
failure, but among all those who had such virological 
failure, about a quarter never achieved virological 
suppression; the average age of this group was less than 
2 years.
Evidence from treatment programmes supports the 
feasibility and beneﬁ  ts of antiretroviral therapy, even in 
highly under-resourced settings,
6 and the results from 
PLATO II need to be considered in context: more than a 
quarter of patients in the cohort had started treatment 
before 2000 when less potent treatments were used and 
treatment guidelines were poorly standardised.
Nevertheless, these data raise several concerns. 
Although the overall rate of triple-class virological 
failure was low, treatment durability is more crucial in 
children than in adults. Achieving sustained virological 
suppression is the goal irrespective of the patient’s 
age, and the fact that very young children might never 
achieve virological suppression is cause for concern. 
For young children, whose adherence depends on 
caregivers, treatment options are extremely limited and 
poorly adapted. Of the 22 antiretroviral drugs currently 
approved by the US Food and Drug Administration, 
ﬁ  ve are not approved for use in children and six are 
not available in paediatric formulations.
7 Additionally, 
treatment has to be constantly adjusted for bodyweight, 
and most paediatric antiretrovirals are formulated as 
syrups (often in large volumes) which are diﬃ   cult to 
administer and store, while boosted protease inhibitors 
are extremely unpalatable. Such complications con-
tribute to the explanation of why, in PLATO II and other 
studies,
8,9 children are more prone to virological failure 
than are adults.
These issues are all the more important in resource-
limited settings, where over 90% of children living 
with HIV/AIDS reside. WHO and treatment providers, 
such as Médecins Sans Frontières, are pressing for more 
widespread use of solid formulations, including ﬁ  xed-
dose combinations. Currently only four quality-assured 
triple-drug ﬁ  xed-dose combinations are available in solid 
and dispersible forms from manu  facturers of generic 
drugs, and less desirable dose formulations continue to 
dominate this small and fragmented market.
10 WHO’s 
S
c
i
e
n
c
e
 
P
h
o
t
o
 
L
i
b
r
a
r
y
 
Transmission electron micrograph of HIV virionsComment
2  www.thelancet.com   Published online April 20, 2011   DOI:10.1016/S0140-6736(11)60363-2
eﬀ  orts to issue user-friendly dosing tables are welcome, 
but the fact that newer paediatric antiretrovirals are not 
currently part of WHO’s work on priority medicines for 
maternal and child health is a concern.
11
The development of new ﬁ  xed-drug  formulations 
is hindered by scarcity of clinical data about the use 
of speciﬁ  c drugs in children. Tenofovir has not been 
validated by regulatory authorities for use in patients 
under 12 years of age. No data about the safety of 
efavirenz or atazanavir in younger children are available. 
And new drug classes, such as CCR5 antagonists 
and integrase inhibitors, are not approved for use in 
children younger than 16 years.
12 Drug developers, 
clinical-trial investigators, and drug regulators all have 
a responsibility to prioritise the pursuit of paediatric 
indications for antiretroviral drugs.
The neglect of children in the global HIV/AIDS 
response runs from clinical research to programme 
implementation, with children receiving a lower 
standard of care than do adults. Paediatric HIV/AIDS is, 
for the most part, a disease of developing nations, where 
there are few proﬁ  t prospects for drug companies. The 
fact that the Drugs For Neglected Diseases Initiative,
13 
a partnership originally established to develop drugs 
for tropical diseases, has recently included paediatric 
HIV/AIDS in its portfolio is telling: paediatric HIV/AIDS is 
a neglected disease.
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